Greven K M, Keyes J W, Williams D W, McGuirt W F, Joyce W T
Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1030, USA.
Cancer. 1999 Jul 1;86(1):114-8. doi: 10.1002/(sici)1097-0142(19990701)86:1<114::aid-cncr16>3.0.co;2-e.
Patients who present with squamous cell carcinoma metastatic to cervical lymph nodes and no clinically apparent primary site present a therapeutic dilemma. Positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose (FDG-PET) has been shown to be useful for the examination of known primary tumors. This study was undertaken to determine whether FDG-PET imaging improves detection of occult primary tumors in patients with metastatic squamous cell carcinoma in the lymph nodes of the head and neck.
Thirteen patients with pathology proven cervical lymph node metastases from clinically occult primary squamous cell carcinomas were evaluated prospectively with FDG-PET, in addition to standard clinical and radiographic techniques, as part of their pretreatment diagnostic evaluation. Direct panendoscopy and biopsy were performed on all patients in an attempt to detect primary tumor sites and to characterize them histologically.
A primary squamous cell carcinoma was confirmed after panendoscopy and biopsy in 3 of the 13 patients. The site of the primary tumor was correctly identified with FDG-PET in only one of these three patients. The FDG-PET study suggested a primary tumor location where no tumor was found in 6 of 13 patients; for 5 other of the 13 patients, the FDG-PET results were negative and no primary was found. No primary tumor locations were identified by computed tomography, magnetic resonance imaging, or direct panendoscopy. FDG-PET imaging correctly detected the location of the primary tumor in 1 patient (8%) and provided apparent false-positive results for 6 (46%) of the 13 patients.
FDG-PET imaging did not significantly improve detection of unknown primary squamous cell carcinomas in patients with metastases to lymph nodes of the neck. A high percentage of results were apparent false-positive.
对于出现鳞状细胞癌转移至颈部淋巴结且临床上未发现明显原发部位的患者,治疗上存在两难困境。正电子发射断层显像术使用2-[F-18]氟-2-脱氧-D-葡萄糖(FDG-PET)已被证明对已知原发性肿瘤的检查有用。本研究旨在确定FDG-PET显像是否能提高对头颈部淋巴结转移性鳞状细胞癌患者隐匿性原发性肿瘤的检测率。
13例经病理证实为临床隐匿性原发性鳞状细胞癌颈部淋巴结转移的患者,除了接受标准临床和影像学检查技术外,还接受了FDG-PET前瞻性评估,作为其治疗前诊断评估的一部分。对所有患者进行直接全腔镜检查和活检,试图检测原发性肿瘤部位并进行组织学特征描述。
13例患者中有3例在全腔镜检查和活检后确诊为原发性鳞状细胞癌。在这3例患者中,只有1例通过FDG-PET正确识别了原发性肿瘤的部位。FDG-PET研究提示13例患者中有6例存在原发性肿瘤部位但未发现肿瘤;另外13例患者中有5例FDG-PET结果为阴性且未发现原发性肿瘤。计算机断层扫描、磁共振成像或直接全腔镜检查均未发现原发性肿瘤部位。FDG-PET显像正确检测出1例(8%)原发性肿瘤的部位,13例患者中有6例(46%)出现明显假阳性结果。
FDG-PET显像并未显著提高对颈部淋巴结转移患者未知原发性鳞状细胞癌的检测率。出现假阳性结果的比例很高。